NEWRON PHARMACEUT. EO-20 (NP5) — Strategic Asset Allocation Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Strategic Asset Allocation Index of 18.6% as of December 2021. Strategic assets (PP&E of €577.00K plus long-term investments of €-) total €577.00K, measured against net assets of €3.11 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
NEWRON PHARMACEUT. EO-20 Strategic Asset Allocation Index (2016–2021)
This chart shows how NEWRON PHARMACEUT. EO-20's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2021. As of December 2021, the index stands at 18.6%, representing strategic assets of €577.00K against net assets of €3.11 Million EUR. Explore NEWRON PHARMACEUT. EO-20 (NP5) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for NEWRON PHARMACEUT. EO-20 (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for NEWRON PHARMACEUT. EO-20 from 2016 to 2021, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see NP5 stock market capitalisation.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 18.6% | €577.00K | €577.00K | €- | €3.11 Million | ▲ +14.3 pp |
| 2020 | 4.3% | €734.00K | €734.00K | €- | €17.25 Million | ▲ +3.6 pp |
| 2019 | 0.7% | €252.00K | €252.00K | €- | €36.80 Million | ▲ +0.0 pp |
| 2018 | 0.7% | €374.00K | €374.00K | €- | €54.84 Million | ▲ +0.5 pp |
| 2017 | 0.2% | €107.00K | €107.00K | €- | €67.72 Million | ▼ -0.1 pp |
| 2016 | 0.2% | €120.00K | €120.00K | €- | €49.75 Million | — |